Lexaria Bioscience Corp. (LEXX)
1.41
+0.18
(+14.63%)
USD |
NASDAQ |
Dec 12, 14:47
Lexaria Bioscience Cash from Financing (Quarterly): 0.00 for Aug. 31, 2025
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Oncolytics Biotech, Inc. | 3.043M |
| Aurinia Pharmaceuticals, Inc. | -10.36M |
| Edesa Biotech, Inc. | 0.4187M |
| Xenon Pharmaceuticals, Inc. | 2.392M |
| ProMIS Neurosciences, Inc. | 21.26M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -2.642M |
| Cash from Investing (Quarterly) | -0.1579M |
| Free Cash Flow | -10.55M |
| Free Cash Flow Per Share (Quarterly) | -0.1358 |
| Free Cash Flow to Equity (Quarterly) | -2.650M |
| Free Cash Flow to Firm (Quarterly) | -2.657M |
| Free Cash Flow Yield | -41.55% |